AstraZeneca, a global, innovation─driven biopharmaceutical business and MedImmune, its global biologics research and development arm, announced that the Japanese Ministry of Health, Labour and Welfare approved Imfinzi (durvalumab)
Original Article: AstraZeneca's Imfinzi gets approval in Japan for NSCLC